# Medicare's $50 GLP-1 Bridge Goes Live July 1 - The Obesity-Drug Pipeline - Week of June 29, 2026

> Issue #1 of The Obesity-Drug Pipeline: for the week of June 22-29, 2026, podcast operators and analysts map Medicare's $50 GLP-1 Bridge Program, Lilly's widening lead, and retatrutide resetting the efficacy ceiling.

## The Obesity-Drug Pipeline

### Week of June 29, 2026: Medicare's $50 GLP-1 Bridge Goes Live July 1

---

*The Obesity-Drug Pipeline, Issue #1, June 29, 2026*

**TL;DR**

- **Medicare flips the switch.** A federal "Bridge Program" puts branded GLP-1s, Wegovy, Zepbound and Lilly's new oral semaglutide "Foundayo," at a flat **$50/month** patient copay from **July 1, 2026 through December 2027**, with Washington paying manufacturers roughly **$245–254/month**. Volume tailwind, net-price question mark. [(NEJM Interviews)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjk9XmTMNu2o7EDblubrzURPcMUUbdvR5Kk4Svq9Ee0o9CoBl-2BZi-2BVb1Eu-2B2ciZtetIDUoHwnMAWjJbVAfDshHQ-2BNX8j0Vdis25NssN2cD2hQ-3D-3D5FNz_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yccYRB6IOWkN-2FdAigr8nOMrF41jcSjobbor-2BEYQ2Eu-2BSCrttZNmJ7WS6gZR7VotWaEO9h9lE-2BHhjIuAKisyP27t8gXzNt7UEi0Jn-2F1F7TKkjQGQt2f1Ze6qgvoWzU1nFYw-3D-3D)
- **Lilly's lead just widened.** Q1 2026 put Mounjaro at **$8.66B**, dethroning Keytruda as the world's top-selling drug, while Ozempic and Wegovy *fell* sequentially. The tirzepatide franchise is tracking past **$52B** for 2026. [(Citeline Scrip)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3DfGVw_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yTMjqzEccT0Fuu33bN8ucAsjfGx8dcgG03OTqOa7HMixneSXVvKyPkix6LRhXYUKAh1PmZi6JxPclCHNq3rYp4GsxZsiBTmhU-2BuFnuLzZ203BfaX3uScig7B7B9ZEbtCOQ-3D-3D)
- **Retatrutide is the real headline.** Fresh ADA data: **~30% weight loss at 104 weeks**, bariatric-surgery territory, and one well-connected 79-year-old already got it via FDA Compassionate Use. [(The Readout Loud)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFDQXz2YItfzuVKURplPMJV9qL6u0uAPqB7Nk027j4By0WCJQW-2BbREA5j-2FPEzigaB9s8lZUaAgn5e6fbnnVPl8cQ-3D-3Dk3ga_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5ybJmVX2pCe-2B9YNByBb-2FTwb2nSnEQg-2B3HjeuPltvoK6xaYiRxj-2F6WqgwxdZSaVz2-2BEBRHGj17RFmbOHZCoAAbsWCR6OvqfcP94CXW-2BLzceT5QxT4Ycp2s2BtOPuCxtp3yfA-3D-3D)

---

A quiet pre-July-4th week on the tape turned out to be anything but. The podcast feed this week was dominated by two things that actually move the model: the mechanics of the Medicare GLP-1 Bridge Program going live Wednesday, and a wave of post-ADA pipeline data that, once again, bends toward Lilly. Here's what mattered.

**The Medicare Bridge Program is the volume story of the year, and the net-price risk.** On *NEJM Interviews*, Vanderbilt drug-pricing economist **Stacie Dusetzina** walked through a program that lets Medicare Part D enrollees obtain GLP-1s for weight loss at roughly **$50/month versus a ~$350 cash price**, running July 2026 to December 2027 [(NEJM Interviews)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjk9XmTMNu2o7EDblubrzURPcMUUbdvR5Kk4Svq9Ee0o9CoBl-2BZi-2BVb1Eu-2B2ciZtetIDUoHwnMAWjJbVAfDshHQ-2BNX8j0Vdis25NssN2cD2hQ-3D-3DMbXJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yeMfm3rkWN5zSKujdiyYv7Pub-2FowVihAnZss4P2eONFEaUXF2k8-2BmZIx3CJ8bCAoIiUNhbYHCBOghTQImLH72in9EAe-2Fm3AATK4flF2-2BSClDPjPb6Y3mvJDafFVLFCxfdA-3D-3D). Obesity-medicine physician **Dr. Carolyn Francavilla** put numbers on the other side of the ledger: the government pays manufacturers about **$245/month**, and eligibility is wide, **BMI 35+ qualifies automatically, BMI 27+ with a comorbidity** [(The Dr. Francavilla Show)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhSO6pDEKyEHu9mv5TPSvfdDrXsNra9KLT3CSj78UEcdnZ-2Bg5HNOvSJDvTLTWPXVWYmf5ZueV97-2BzNAw3DQCWwPhVb3sb8yGiMSYHtHKxnbhw-3D-3DIomm_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yU0iPY9VrS1CkvAqk7QJ-2FDfD5Qg1NdGmX08HV-2BpOjFGtQ6MmRmYSRX4d4Ff61L5K8PIBtuyWRzKkjCAkFOzNxNW0J-2FYJ3QM8q-2B4AogVuejNnHR08aiqucGF0zkCH2bAq7A-3D-3D). On *On The Pen*, **Dr. Angela Fitch** (CMS consultant) pegged the manufacturer payment at **$254/month** and reminded listeners that **110 million** Americans live with obesity [(On The Pen)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgzXBuUkzihOOvDgKuAxjMiF8pdHMjMWHqUbuJK6Plyo8X2IQFcgA41Q20DHZ-2BfBA-2FHLUgewlcBgqd2awgIwfv8CbJ6RV5Qi4Tl-2FmF6dwsQJQ-3D-3D9Dl8_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yekqpgnMNWobO-2FOLJwo7sitjbfgFckPr-2BIYKyI-2FTottZ5sgicx0TufCzV5UcXeEq5szUt3F-2F-2Bp3LqJODq76DLpj7mYWqFVjbn4hCVFcKPGmIKcLkiJAT2KUacggixD8nEQ-3D-3D). Translation for the book: a giant new covered-life cohort opens up, but it opens at a *negotiated* price, exactly the dynamic the bears keep pointing to.

**Lilly's Q1 print reframed the duopoly as a near-monopoly of growth.** Per *Citeline's Scrip*, **Mounjaro booked $8.66B in Q1 2026, more than doubling year-on-year, ending Keytruda's reign as the world's best-selling drug**, with ex-US sales of **$4.4B overtaking US sales for the first time**. Zepbound added **$4.16B**, putting the tirzepatide franchise at **$12.8B for the quarter**. Meanwhile **Ozempic fell $602M and Wegovy fell $551M** sequentially. Consensus has Mounjaro taking the **2026 annual crown at $33.1B**, Zepbound at $19.3B, and the four big GLP-1 brands combining for **~$80B** [(Citeline Scrip)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3DMbGh_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yd9gHmootza1unsyJm-2BYSD7c5vENoSOSxM5EGhgQukxyhPzvgI-2Bs3RIJgrNxtOljts-2F9TFE0CA-2FfPwD6vHPxJ7XRyQEWBFGdE2ObAHJIcEE1cQQgtSGRi0Vjk-2FJ8cz9FGQ-3D-3D). *Motley Fool's Capital Ideas* crew noted tirzepatide is now **more than half of Lilly's revenue, with patents running to 2036** [(Motley Fool Hidden Gems)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjyURSFmVXNpM6h7YYJpBXB34Q4DoQiWhxGUvL6KsBt0tYWUA5OTYERq5hlD-2FLb1LfPjuvr88NtLwRVappsEK4bVi1xNoPfVaOsk-2FDvTTuGXQ-3D-3D0uuq_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yZYmbRRgsz3vsxJjFX7FyA3qQ44pp6P4R55Q8flw02qJMeH8LsINPgp5QJQwIWpB-2BZufkMfgQpswGQ-2BbmvC5d6fGqVVtaMtlOK5pkdpVr-2BME3S-2FcGLPLxhRiQgTcdGTJsQ-3D-3D).

**Retatrutide's data is the kind that resets a TAM.** On *The Obesity Guide*, **Dr. Matthea Rentea** walked the 80-week Phase 3: **mean weight loss of 28.3% at the 12mg dose**, with **62.5% of patients losing ≥25%** of body weight, but with a tolerability tax: discontinuations of **4.1% / 6.9% / 11.3%** across doses and nausea climbing to **42%**, vomiting to **25%** at top dose [(The Obesity Guide)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiV2zqYIFaqCn10B5qpbhhWay8Y75Qa3q-2BixTCstrPHO5x7XxkvvvglvWfRE9W5J8DYWr-2BBLVMkSO9PRzjGm5R-2Fi1D5PIkzfS-2FcP7iDfk0AVg-3D-3DUNzi_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5ySF0kOXm2ohI82qyhEUVpvD8ar2-2Fq8epTjMSkQ5ZqcmDoSBdV43OX-2BiKEb-2FsXKJBOi1n5unU8tc5-2FGbECZXgMMb6ele1EDX9vnajMdR88kN3jeFnP1dCaDM63OmJ1XzF9A-3D-3D). On *DOC Updates* (episode sponsored by Lilly), KOL **Dr. Juan Frias** put the 104-week TRIUMPH-1 figure at **~30% weight loss, up to ~45% in heavy responders**, plus wins in knee osteoarthritis and sleep apnea sub-studies [(DOC Updates)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhS04n7SAiZkNhORyjYmpC-2F0IDtd4PW02VJ2RIRZTG4JxVFOELwWe5ftKNpi8rEeLXI8O72yEyVcI9Ae4ZkgutewTgFwhyQ-2BLP3pJzh4O8PQw-3D-3D78Ed_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yRdQ741aJFcICk3RAbGonH-2FLmUvxZVrts3P-2BhQWUqgWCqCcaHZwO9ncGav08BK2hWrwDDorTKFy5y5dlvikhpwW-2FIuGfUYbKH9-2F6vckJr3m2pkrxab-2FlHvWEFEXIPyJkpg-3D-3D). And *STAT's Readout Loud* reported the curiosity of the week: a **79-year-old, well-connected man** got early access to retatrutide through FDA Compassionate Use, the White House denied it was the President [(The Readout Loud)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFDQXz2YItfzuVKURplPMJV9qL6u0uAPqB7Nk027j4By0WCJQW-2BbREA5j-2FPEzigaB9s8lZUaAgn5e6fbnnVPl8cQ-3D-3DTQU9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5ybBDALjI-2BK6O3QeXcTTNgo6Yubqi-2FcrfAYuQi8kBFzIXCLEPEHSqweZHkmd4wNJS6Nl2cnphM93NIrLgV0LKSiAS-2BS2wybsG3JJ6VbeD-2FvM8FlOiFUauurRYmRpTySpBiA-3D-3D).

**The chasing pack has a data-integrity problem.** *Scrip* flagged a real wrinkle for fast-followers: placebo-arm dropout and off-protocol GLP-1 use. Boehringer's **servodutide (SYNCHRONIZE-1)** delivered a solid **16.6% weight loss over 76 weeks** but saw **~20% discontinue on tolerability** and **16% of the placebo arm secretly start Wegovy or Zepbound**, muddying the readout enough to cast doubt on a regulatory filing. Roche's **CT-388** saw a **34% placebo-arm dropout** in Phase 2 [(Citeline Scrip)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3D_s1P_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yaN4YkvcrPaD0wzhhRSY3-2FtEB127SoQUklDtiv0EcVDAcWRgmt2OA28eduB8fyPYghulOG4VfVcVKqu-2FYlJEszEAnW-2F-2BKasjC5MW13M-2B6p09NqbVFaqyus-2FhrUdOGp0Wyw-3D-3D).

---

**The debate**

**Bull:** This is still early innings. One in eight Americans is already on a GLP-1, heading toward one in four [(Health:Further)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiem-2BhV3r7E-2B5Nc72dNYniOe-2FZdmGtI3Rs0e-2FP63rDtbJ7oj-2BI9EEFCI12oaQxs2A0mc-2B9-2BDN03PhWfFEEUkTpT0wnf9gUyE0xrAZ-2B6jlsYwg-3D-3D2DQu_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yUwR-2Bsts9s0FzZC8ZNIhUhjNN5TPztrhl1R0oEt-2F9PtmdT4L5gkws-2BhV2DwQ5-2B8s5LP43eC9LYv3Fq7xHTm1falTq6Hujfy2-2FyiLQXNJWBfiRW-2FPyv9vCLdTaBi7L0WrAg-3D-3D), and the cost-benefit math keeps improving, a symposium economist pegged obesity-treatment ROI at **$3.81 per dollar in Medicaid, $3.09 commercial** over five years [(DOC Updates, CARE Symposium)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgp2GSdCl5PXxMimT6MOoMEEJbAFXEb4JIlaQ61DjAAQttXTxlfXVySsQ2E6ClMiLToDrXBrZ2H96vD-2FWhrjkgFEiTkElH2N-2FVmPDHN7AE6zQ-3D-3DbLc6_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yX0-2FDeP4YHaYT-2BI8MRbUVOX5WTd2SWh8SQxqYihhRibyqSlUspgYIB73mgTdR4VOh85MNVFxedr4yi1-2FMh02cW5jvsMq8c5UF2VkQFdkIk447Bg5eItcHPoDuEe9yaSq8w-3D-3D). Medicare coverage expands the funnel; next-gen efficacy (retatrutide, oral agents) deepens it. TAM compounds toward double-digit penetration with Lilly setting price.

**Bear:** GLP-1s already eat **>20% of total drug spend at some large pharmacy coalitions** [(Actuary Voices)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgq4-2BX7uJGZCb7Vdw7UnNvTScGvnn93RPg8JmXSkntQduEM9ioZLpKWGLfEzKEjLIp-2FmPp7ffALQ7UeG9MaoyOKCQHfbQM3nQkHEi8HUkX3Xw-3D-3DyXbJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yfwBHiUZGl34V1BAzZbHfW6VvyizdD9atVfEygHUGuQqCrEWmByrN0PEcX2ovf4YPIK7gweR5dUxifI0qGEiJgdNYEBI0gyFWFA9EsmAJoJvKoJVJRrA83iJLBCDJ0FtVQ-3D-3D), and that's before a Medicare program that *negotiates* the manufacturer price down to ~$245/month. Add a crowded next-gen field, semaglutide patent expiries (Brazil already this March), and compulsory-licensing noise abroad [(Citeline Scrip)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3DKAcJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yao3I6t4XBNZAw0G13trAdCYEQyAKMR2ta45g-2FoVDCbb8Bfcv9sSptx2nPY7pn-2F6oW40mgGi1N-2FzZfT9yh69jAfzM0uvWSzvIbivLItXewr7E9SYvHpnuukVmZKeHnSa7Q-3D-3D), and net price compresses faster than the Street's volume models assume.

*Read on the week:* the tape argues volume and net price are **decoupling**, the unit story has never looked better, but every catalyst (Medicare, generics, the chasing pack's price competition) points the *per-script economics* the other way. Own the share-gainer that controls pricing; treat the laggards as price-takers.

---

**Stocks in play**

| Ticker | Bull case | Bear case | Next catalyst |
| --- | --- | --- | --- |
| **LLY** | Mounjaro now #1 drug globally ($8.66B Q1); franchise tracking >$52B in 2026; retatrutide ~30% weight loss extends moat to 2036 patents | Tirzepatide is >half of revenue, concentration risk; Medicare negotiates price down | Retatrutide regulatory path; oral "Foundayo" ramp [(Scrip)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3DZQTu_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5ycXtO1zV9a-2BRj9m3V80kgLuilIY2awMGqC5RcDohjWYgJ81Vw3ubfNQXCu68ZKt9BF9MwxoR18sXxmZye8rJURxL37QvYeRSEK-2FU-2BV55tuRqreNaePV7CUIRX-2FxVJg-2B0AA-3D-3D) |
| **NVO** | ~10x earnings vs LLY ~40x; $2.3B buybacks; 9,000 job cuts (~11% of staff); CagriSema beat expectations in diabetes | Ozempic & Wegovy both fell sequentially; stock −45% in a year; CagriSema lost head-to-head, −15%/$100B in a day | CagriSema diabetes label; oral Wegovy uptake [(Wall Street Wildlife)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhBfyTu3jdIhx-2FswqgEmVRVTOZt-2FrtT-2FaYTzsRTeAxitZSWDlUmbQZ0msYDj7HJoPcDbQqw-2BFe2sJUcPtTlPwJSogGOBbiFbWxCw7u5VDp7aQ-3D-3DBzmO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yRLTg3yaQ2KveYotjQqVvVcWFTu7mhhcPkmSk-2B5AKuEzRTdqOVFOnHcTwOiaR-2FJ75CHo05Ue0oUv8hZi3e-2FGHSbvSXQCLxmWTDK5c87DE9ZtjzLuCfxteUeXO-2B8DvsV-2Fog-3D-3D) |
| **AMGN** | MariTide once-*monthly* dosing differentiation; now in Phase 3 | No new ADA data this cycle; behind on efficacy | Phase 3 MariTide readouts [(DOC Updates)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhS04n7SAiZkNhORyjYmpC-2F0IDtd4PW02VJ2RIRZTG4JxVFOELwWe5ftKNpi8rEeLXI8O72yEyVcI9Ae4ZkgutewTgFwhyQ-2BLP3pJzh4O8PQw-3D-3Dsm1u_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yVg5M9z3YrtMyxHyJT9JEMJivHyM6e8RP-2B5aLaxgJfzTlKE1bIKhrUO8DH82SYRzUVQkwcJT2uqsUnY-2Bzrmzu9dN3LevjUC-2FfeYp2T47MDiYRHMfiC-2F9LYmt1mz-2BL13WQw-3D-3D) |
| **Roche** | Cervodutide's liver-specific glucagon effect (12–15% loss) carves a MASH niche | CT-388 Phase 2 hit by 34% placebo dropout | Cervodutide SYNCHRONIZE / CT-996 data [(DOC Updates)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhS04n7SAiZkNhORyjYmpC-2F0IDtd4PW02VJ2RIRZTG4JxVFOELwWe5ftKNpi8rEeLXI8O72yEyVcI9Ae4ZkgutewTgFwhyQ-2BLP3pJzh4O8PQw-3D-3DhSbg_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5ybDBzAzNFbyEdtA6MuaC4uPxV-2FGeCWIBlomn0yS0SRoOWKiyvbuw7ZGnOvuZzHvSGbqNa207C1rPsrZOMXqukc4hwFMsKIF8x2fkqNl3w-2BX4ic3T8VEiwL1TRgxYREvN-2Fw-3D-3D) |
| **Boehringer (pvt)** | Servodutide 16.6% at 76wks; visceral/liver-fat data | ~20% tolerability dropout; filing in doubt | Decision on regulatory submission [(Scrip)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3DnuZ3_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5ySVfj1St5pKf-2BcSO2Aa3bNVqHWwNvmF1rPd52YolV0IbU0ZjNnyCb6DN2SscUKrisQNRpp4b-2BQog20Rxwv6u0ljEavp-2BvIaD-2FzWoi-2B96Los-2F5eN9IYtJzkr4BMroMpPvzg-3D-3D) |

*VKTX (VK2735) was named only in passing this week, no fresh data on the tape.*

---

**Read-throughs**

- **Fast-followers (AMGN, VKTX, Roche, Boehringer):** the efficacy bar is now retatrutide's ~30%. Amylin analogs (cagrilintide, petrelintide) showed **10%+ weight loss with near-placebo tolerability** [(DOC Updates)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhS04n7SAiZkNhORyjYmpC-2F0IDtd4PW02VJ2RIRZTG4JxVFOELwWe5ftKNpi8rEeLXI8O72yEyVcI9Ae4ZkgutewTgFwhyQ-2BLP3pJzh4O8PQw-3D-3Dcs67_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yTLLoUYOe321WfntSRKffoeIqPD7FjxwTJULSHkwFtuWtbnyIZn5eJGLDWqOm5CFgF4YBdOkS73dUgyuXnuthaF5N1srCw6ER-2B-2B-2F7LQ-2FYzrsYdQe23pp-2Bw1YAChVDnw0SQ-3D-3D), the differentiation game is shifting from raw weight loss to *tolerability* and dosing convenience (monthly, oral).
- **Contract manufacturing / fill-finish (CTLT, LNZA, TMO):** No CMO-specific commentary this week, notable given a Medicare volume surge lands Wednesday. Watch for supply commentary into next quarter.
- **Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize):** Zero episodes. The shift toward *oral* agents (Foundayo, oral amycretin) is a slow-burn risk to injector demand worth tracking.
- **Insurers / PBMs (CVS, CI, UNH):** addressed only obliquely via the Medicare Bridge mechanics; no formulary or PBM-specific decision surfaced. The 503A/B compounding fight showed up mostly as consumer "$50 GLP-1" access chatter [(On The Pen)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgzXBuUkzihOOvDgKuAxjMiF8pdHMjMWHqUbuJK6Plyo8X2IQFcgA41Q20DHZ-2BfBA-2FHLUgewlcBgqd2awgIwfv8CbJ6RV5Qi4Tl-2FmF6dwsQJQ-3D-3D9TgM_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yb5N8AqLiP1ug9P9ApEBtNgjjjj2fLUczvwse-2FiKZWvcZWA42A8e-2BuUa1v0HbxM-2FI2HtQRE325-2F-2FQh9gcSdkKrxxsfYutZAMvbgoGdlCstWCYzE4Op2y7RtGb-2B2vo3q0Xg-3D-3D).
- **Medtech / bariatric:** retatrutide's "bariatric-level" framing is a structural overhang on surgical volumes, reiterated, not new.
- **Food / QSR:** little on the tape this week.

One genuine operator voice cut through: **Mark Clermont, CEO of Cecelia Health**, framed GLP-1s as a drug *class* now crossing diabetes, obesity, sleep apnea and beyond, and flagged Lilly's oral pill "Fondio/Foundayo" and the broader pipeline (CagriSema, retatrutide, servodutide, MariTide, Viking) as a management challenge, not just a tailwind [(Slice of Healthcare)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiS1sLwoDG73ar5cCuecT5WwW5dUi-2Bn9gOkLSIny4qjkgn-2BJ4-2FyQxp-2B6tTelRg-2Fnkc09D3xaqqWH00rgfJ-2BDhzSUM-2Bep2CziFOJ3YR7rddolA-3D-3DZBSL_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbVypZvixm8qk6nz9FeLBB4yb-2FZla6Ms4svLvyrzJVu5yUVByJYQ1eC18F8-2Fnqgk2-2FQCahZATZScR1kDp77YV7biZB-2FlW5GLOE4tMtvTLpq4SHiWYv5dsSRczT9A4WnDmQZwexN1a64KaDGpWaZgXLwbLaAMww-2FAkrjXYXsEU1KiAQ-3D-3D).

**What changed vs. last week**

This is **Issue #1** of the series, no prior issue to diff against. Baseline established: Lilly extending its lead, Medicare coverage going live July 1, retatrutide setting the new efficacy ceiling. Worth flagging when they wake up: contract manufacturers, injector-pen suppliers, US state legislation (Tennessee Fair Rx Act), a dedicated Novo Capital Markets Day, and hard weekly TRx/NRx script-tracker data.